Madrigal Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
16analysts covering
FY Revenue (est.)
$1.5Bnext fiscal year
FY EPS (est.)
-$6.49next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 29 Oct 2026 |
| Q4 2026 Earnings Release | 25 Feb 2027 |
Monitoring Framework
Key Performance Indicators
Rezdiffra (resmetirom) Net Sales Quarterly311.3MTarget: Blockbuster status on a trailing-12-month net sales basis
Number of Patients on Rezdiffra Quarterly42.3KTarget: Steady patient additions to address a diagnosed F2/F3 population of ~460,000
Cash, Cash Equivalents, Restricted Cash and Marketable Securities Quarterly817.9MTarget: Maintain sufficient runway to support commercial launch and pipeline expansion
Watch Items
- MGL-2086 (oral GLP-1) Phase 1 Trial InitiationTrigger: Initiation of Phase 1 trial in Q2 2026Action: Monitor clinical trial registry updates and company press releases for official study start
- Ervogastat/resmetirom Drug-Drug Interaction StudyTrigger: Initiation of study in Q4 2026Action: Track regulatory filings and clinical development updates in late 2026
- Rezdiffra Phase 3 Outcomes Trial in Compensated MASH Cirrhosis (F4c)Trigger: Event-driven outcomes readout expected in 2027Action: Evaluate interim data announcements and event accumulation rates
Research as of 2 Sep 2026